Key result
Higher copeptin linked to ~15% greater all-cause mortality risk per SD in renal impairment.
Why the study?
In chronic kidney disease, arginine vasopressin is upregulated and may contribute to increased cardiovascular and infectious complications, but its surrogate copeptin's association with cause-specific mortality across renal function spectrum was unclear.
Is copeptin concentration associated with cause-specific mortality in patients with impaired renal function?
Cohort (n=4,372)
Yes
Is copeptin concentration associated with cause-specific mortality in patients with impaired renal function?
Hazard Ratio: 1.15 (95% CI 1.05–1.25)
Higher copeptin concentrations are independently associated with increased risk of coronary, infectious, and all-cause mortality in patients with renal impairment, but not in those with normal renal function.
May refine mortality risk assessment in renal impairment; observational data leave open causal and therapeutic implications.
BACKGROUND In chronic kidney disease (CKD) arginine vasopressin (AVP) cannot efficiently act via renal V2-receptors. AVP is upregulated leading to augmented activation of V1a- and V1b-receptors, which might contribute to the increase in cardiovascular and infectious complications in CKD. Here, we evaluate copeptin, a surrogate of AVP, and its association with cause specific mortality among patients within the whole spectrum of renal function. METHODS Copeptin was measured in baseline samples from the LURIC (n = 3131 patients with coronary angiograms) and the 4D-Study (n = 1241 type 2 diabetic hemodialysis patients). Patients were stratified into 4 groups: estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m2, 60–89 mL/min/1.73 m2, <60 mL/min/1.73 m2, and hemodialysis. The association of copeptin with mortality was assessed by Cox proportional hazards regression during 9.9 years of median follow-up in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study and 4 years of median follow-up in the German Diabetes Dialysis Study (4D-Study). RESULTS Median copeptin increased with decreasing eGFR: 5.6 [interquartile range (IQR), 3.1–8.1] pmol/L (eGFR ≥90 mL/min/1.73 m2), 6.7 (2.9–10.5) pmol/L (eGFR 60–89 mL/min/1.73 m2), 15.3 (6.7–23.9) pmol/L (eGFR <60 mL/min/1.73 m2), and 80.8 (51.2–122) pmol/L (hemodialysis), respectively. Per SD increase in copeptin, the risk of coronary, infectious, and all-cause mortality increased by 25, 30, and 15% [hazard ratios (HR), 1.25; 95% CI, 1.13–1.39; HR, 1.30; 95% CI, 0.98–1.71; and HR, 1.15; 95% CI, 1.05–1.25], respectively, in patients with eGFR 60–89 mL/min/1.73 m2. Except for coronary death, results were similar among patients with more advanced renal disease. No significant association was found in patients with normal renal function. CONCLUSIONS Copeptin concentrations were independently associated with coronary, infectious, and all-cause mortality in patients with renal impairment. In patients with normal renal function no significant association was found.
No takes yet. Share an insight, caveat, or question.
Krane et al. (2017) conducted a cohort in Chronic kidney disease (n=4,372). Copeptin vs. Lower copeptin levels was evaluated on All-cause mortality (HR 1.15, 95% CI 1.05-1.25). Per standard deviation increase in copeptin, the risk of all-cause mortality increased by 15% (HR 1.15; 95% CI 1.05-1.25) in patients with mild to advanced renal impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: